4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
7.89
-0.52 (-6.18%)
Nov 21, 2024, 1:23 PM EST - Market open
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for FDMT stock have an average target of 46.75, with a low estimate of 36 and a high estimate of 81. The average target predicts an increase of 492.52% from the current stock price of 7.89.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for FDMT stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $39 | Strong Buy | Maintains | $39 | +394.30% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +356.27% | Nov 14, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $40 → $39 | Buy | Maintains | $40 → $39 | +394.30% | Nov 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 23, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $38 → $39 | Strong Buy | Maintains | $38 → $39 | +394.30% | Sep 19, 2024 |
Financial Forecast
Revenue This Year
6.05M
from 20.72M
Decreased by -70.79%
Revenue Next Year
9.56M
from 6.05M
Increased by 57.85%
EPS This Year
-2.86
from -2.58
EPS Next Year
-3.36
from -2.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.1M | 22.1M | 18.9M | ||
| Avg | 6.1M | 9.6M | 6.9M | ||
| Low | 29,400 | n/a | 1.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.4% | 264.2% | 97.8% | ||
| Avg | -70.8% | 57.8% | -28.2% | ||
| Low | -99.9% | - | -80.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.64 | -0.96 | -2.89 | ||
| Avg | -2.86 | -3.36 | -3.76 | ||
| Low | -3.01 | -4.18 | -4.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.